180 related articles for article (PubMed ID: 28584849)
1. Carbapenem-Resistant
Alexander EL; Loutit J; Tumbarello M; Wunderink R; Felton T; Daikos G; Fusaro K; White D; Zhang S; Dudley MN
Open Forum Infect Dis; 2017; 4(2):ofx063. PubMed ID: 28584849
[TBL] [Abstract][Full Text] [Related]
2. Factors associated to prevalence and treatment of carbapenem-resistant Enterobacteriaceae infections: a seven years retrospective study in three tertiary care hospitals.
Pang F; Jia XQ; Zhao QG; Zhang Y
Ann Clin Microbiol Antimicrob; 2018 Mar; 17(1):13. PubMed ID: 29571291
[TBL] [Abstract][Full Text] [Related]
3. Carbapenem-resistant Enterobacteriaceae: A retrospective review of treatment and outcomes in a long-term acute care hospital.
Igbinosa O; Dogho P; Osadiaye N
Am J Infect Control; 2020 Jan; 48(1):7-12. PubMed ID: 31431290
[TBL] [Abstract][Full Text] [Related]
4. Development of a bedside tool to predict the probability of drug-resistant pathogens among hospitalized adult patients with gram-negative infections.
Lodise TP; Bonine NG; Ye JM; Folse HJ; Gillard P
BMC Infect Dis; 2019 Aug; 19(1):718. PubMed ID: 31412809
[TBL] [Abstract][Full Text] [Related]
5. A Cohort Study of the Impact of Carbapenem-Resistant
Sabino S; Soares S; Ramos F; Moretti M; Zavascki AP; Rigatto MH
mSphere; 2019 Apr; 4(2):. PubMed ID: 30971443
[TBL] [Abstract][Full Text] [Related]
6. Novel pharmacotherapy for the treatment of hospital-acquired and ventilator-associated pneumonia caused by resistant gram-negative bacteria.
Kidd JM; Kuti JL; Nicolau DP
Expert Opin Pharmacother; 2018 Mar; 19(4):397-408. PubMed ID: 29411661
[TBL] [Abstract][Full Text] [Related]
7. EUropean prospective cohort study on
Gutiérrez-Gutiérrez B; Sojo-Dorado J; Bravo-Ferrer J; Cuperus N; de Kraker M; Kostyanev T; Raka L; Daikos G; Feifel J; Folgori L; Pascual A; Goossens H; O'Brien S; Bonten MJ; Rodríguez-Baño J;
BMJ Open; 2017 Apr; 7(4):e015365. PubMed ID: 28373258
[TBL] [Abstract][Full Text] [Related]
8. Complicated carbapenem-resistant infections: a treatment pathway analysis in Italian sites.
Durante-Mangoni E; Bertolino L; Mastroianni C; Viale P; Bassetti M; Citton R; Gómez-Ulloa D; Roset M; McCann E
Infez Med; 2021; 29(3):434-449. PubMed ID: 35146349
[TBL] [Abstract][Full Text] [Related]
9. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
[TBL] [Abstract][Full Text] [Related]
10. Improving Conduct and Feasibility of Clinical Trials to Evaluate Antibacterial Drugs to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia: Recommendations of the Clinical Trials Transformation Initiative Antibacterial Drug Development Project Team.
Knirsch C; Alemayehu D; Botgros R; Comic-Savic S; Friedland D; Holland TL; Merchant K; Noel GJ; Pelfrene E; Reith C; Santiago J; Tiernan R; Tenearts P; Goldsack JC; Fowler VG
Clin Infect Dis; 2016 Aug; 63 Suppl 2():S29-36. PubMed ID: 27481950
[TBL] [Abstract][Full Text] [Related]
11. Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis.
Zilberberg MD; Nathanson BH; Sulham K; Fan W; Shorr AF
BMC Infect Dis; 2017 Apr; 17(1):279. PubMed ID: 28415969
[TBL] [Abstract][Full Text] [Related]
12. Treatment options and clinical outcomes for carbapenem-resistant Enterobacteriaceae bloodstream infection in a Chinese university hospital.
Li C; Li Y; Zhao Z; Liu Q; Li B
J Infect Public Health; 2019; 12(1):26-31. PubMed ID: 30145151
[TBL] [Abstract][Full Text] [Related]
13. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae.
Alraddadi BM; Saeedi M; Qutub M; Alshukairi A; Hassanien A; Wali G
BMC Infect Dis; 2019 Sep; 19(1):772. PubMed ID: 31484510
[TBL] [Abstract][Full Text] [Related]
15. 30-day readmission, antibiotics costs and costs of delay to adequate treatment of Enterobacteriaceae UTI, pneumonia, and sepsis: a retrospective cohort study.
Zilberberg MD; Nathanson BH; Sulham K; Fan W; Shorr AF
Antimicrob Resist Infect Control; 2017; 6():124. PubMed ID: 29225798
[TBL] [Abstract][Full Text] [Related]
16. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology of Carbapenem-Resistant Enterobacteriaceae Infections: Report from the China CRE Network.
Zhang Y; Wang Q; Yin Y; Chen H; Jin L; Gu B; Xie L; Yang C; Ma X; Li H; Li W; Zhang X; Liao K; Man S; Wang S; Wen H; Li B; Guo Z; Tian J; Pei F; Liu L; Zhang L; Zou C; Hu T; Cai J; Yang H; Huang J; Jia X; Huang W; Cao B; Wang H
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203488
[TBL] [Abstract][Full Text] [Related]
18. Retrospective Observational Study from a Chinese Network of the Impact of Combination Therapy versus Monotherapy on Mortality from Carbapenem-Resistant
Wang X; Wang Q; Cao B; Sun S; Zhang Y; Gu B; Li B; Liao K; Zhao F; Jin L; Jin C; Yang C; Pei F; Zhang Z; Wang H
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30348660
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology and risk factors of neurosurgical bacterial meningitis/encephalitis induced by carbapenem resistant Enterobacteriaceae.
Guanghui Z; Jing L; Guojun Z; Hong L
J Infect Chemother; 2020 Jan; 26(1):101-106. PubMed ID: 31445817
[TBL] [Abstract][Full Text] [Related]
20. Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae.
Lee YR; Baker NT
Eur J Clin Microbiol Infect Dis; 2018 Aug; 37(8):1411-1419. PubMed ID: 29675787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
